AlpaLife, an innovator in single domain antibody (sdAb, also called nanobody*) development recently announced its strategic collaboration with a wide variety of sdAb developing organizations including research labs, academic antibody and drug development companies across China.
sdAbs are a new catalogue of antibodies originally discovered in camels with a smaller molecule size and stronger binding affinity than conventional antibodies produced in mouse or rabbit. Different from conventional antibodies that can be produced in almost all higher organisms, sdAbs can be only produced in a few species including camels, llamas and sharks.
AlpaLife is a special division created by KangTi Co., Ltd., a 2016-established Shenzhen-based company focusing on the development and production of sdAbs in academic research, medical diagnostics and drug development. Collaboration with outstanding industry partners and research labs is an important part of AlpaLife’s strategy to expand the company’s product diversity and promote its drug discovery process. In last month, AlpaLife has signed collaboration contract with academic institutions including Shanxi Agriculture University, Shihezi University and Xiamen University as well as sdAb companies like NBbiolabs and Dajia. By working with those research labs and commercial companies, AlpaLife establishes a comprehensive sdAb development platform covering sdAb selection from camels, llamas and sharks. The variety of species from which the sdAb library is constructed is a key factor affecting sdAb’s sequence variety, which in turn contribute to the acquisition of good candidate during drug development.
With the collaboration with various organizations, AlpaLife is accelerating its sdAb drug development process and becoming the most influential sdAb company in China.